Early detection crucial for hearing health, says audiologist
Audiologist Dr. Sheryl Figliano says hearing is an important health aspect that should not be ignored.
She was doing a hearing test in her office Monday at the Centers for Hearing Care, which she said is beneficial now and in the future.
'The importance of a baseline hearing test, how many things can contribute to hearing health, and if we catch things sooner, the healthier it is for us as we age,' she said.
World Hearing Day on Monday serves as a reminder of the importance of hearing health and early detection. The idea is to raise awareness about how to prevent deafness and hearing loss, plus promote ear and hearing care.
'Patients with untreated hearing loss have a faster rate of cognitive decline, and that's scary,' Figliano said.
Figliano said as people age, they can experience issues like diabetes, circulation problems, high cholesterol and high blood pressure, which can also cause hearing loss.
Dr. Figliano said one of the biggest myths that she hears is that hearing aids are expensive. The newest models are light, hidden and reasonably priced, she said, and they're beneficial to those who need them.
'But if you protect your hearing now, you may not ever need them, and that's the best solution,' she said.
Dr. Figliano recommends foam roll-up ear protectors for those who are in noisy environments, and the Centers for Hearing Care will provide a free pack to those who need them.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
11 minutes ago
- Business Insider
How Kenya fought for decades to eliminate a brain-attacking killer
The World Health Organization (WHO) has formally verified Kenya's elimination of human African trypanosomiasis (HAT), often known as sleeping sickness, as a public health hazard. Kenya has successfully eliminated human African trypanosomiasis (HAT) as a public health concern. This achievement follows years of dedicated surveillance and control measures against the disease. Kenya is now the 10th country globally to attain this milestone and has previously eradicated Guinea worm disease. This makes Kenya the 10th country in the world to attain this milestone, and the second neglected tropical disease (NTD) it has eradicated, following Guinea worm disease in 2018. 'I congratulate the government and people of Kenya on this landmark achievement,' said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. 'Kenya joins the growing ranks of countries freeing their populations of human African trypanosomiasis. This is another step towards making Africa free of neglected tropical diseases'. HAT is a vector-borne parasite illness caused by Trypanosoma brucei and spread to humans via infected tsetse flies. The illness is unique to Africa and exists in two forms: gambiense and rhodesiense. Kenya's bout with the sleeping sickness In Kenya, only the Rhodesiense strain (r-HAT) is found. Found in eastern and southern Africa, r-HAT develops fast, attacking multiple organs, including the brain, and can be fatal within weeks if left untreated. The first incidents in Kenya were documented in the early twentieth century. Since then, the nation has maintained a consistent control strategy. There have been no indigenous instances in almost a decade, with the most recent locally transmitted case occurring in 2009. The final two exported instances, both from the Masai Mara National Reserve, were identified in 2012. Kenya's eradication status follows years of improved disease surveillance in formerly impacted areas. 'This validation marks a major public health milestone for Kenya, as we celebrate the elimination of a deadly disease in our country. The achievement will not only protect our people but also pave the way for renewed economic growth and prosperity,' said Dr Aden Duale, Kenya's Cabinet Secretary for Health. 'This follows many years of dedication, hard work, and collaboration'. Twelve health institutions in six historically endemic counties were selected as sentinel sites, with modern diagnostic technologies and experienced medical workers to perform the most sensitive and feasible r-HAT tests. In addition to human surveillance, Kenya has invested in monitoring and managing tsetse flies and animal trypanosomiasis, all of which are crucial to preventing re-emergence. These efforts, aided by national veterinary health authorities and the Kenya Tsetse and Trypanosomiasis Eradication Council (KENTTEC), have been critical in sustaining the disease-free status. WHO's approval is an important public health success for Kenya, recognizing its long-term efforts to eradicate a disease that formerly presented a danger to rural people reliant on agriculture, fishing, animal husbandry, and hunting. With this success, Kenya joins a growing list of African countries that have demonstrated that focused, well-coordinated health efforts can eradicate even the most tenacious tropical illnesses.
Axios
2 days ago
- Axios
What to know about rising COVID-19 cases and the surging "stratus" variant
COVID-19 cases are rising again in the United States, and the "stratus" variant might be to blame. The big picture: A summer outbreak of COVID-19 cases isn't a shocker. But it's arriving before children head back to school, where the virus could spread even more. The risk of a summertime COVID-19 wave comes after Health Secretary Robert F. Kennedy Jr. unilaterally changed federal COVID vaccine recommendations, causing confusion over who should get the shots. COVID-19 cases rising in U.S. Driving the news: The Centers for Disease Control and Prevention on Friday upgraded national wastewater viral activity for COVID-19 from "low" to "moderate." Wastewater levels for COVID-19 are highest in the Western U.S., according to a CDC map, with levels peaking in Alaska, California, Colorado, Nevada and Utah. The Southeast also has higher wastewater activity levels, with Louisiana having the most nationwide, according to CDC data recorded from July 27 to Aug. 2. What they're saying: "Wastewater monitoring can detect viruses spreading from one person to another within a community earlier than clinical testing and before people who are sick go to their doctor or hospital," the CDC says on its website. "It can also detect infections without symptoms. If you see increased wastewater viral activity levels, it might indicate that there is a higher risk of infection." By the numbers: The CDC estimated Friday that COVID-19 cases are likely growing across 45 states. Only four states — Alaska, North Dakota, Maine and New Hampshire — measured as having no change in COVID-19 cases. Wyoming's numbers were not estimated. Though the N.B.1.8.1 variant (nicknamed "nimbus") is still the dominant variant in the U.S., the recent climb might be related to the variant XFG, commonly known as "Stratus." Both are descendants of the Omicron strain. What to know about the "stratus" COVID variant Flashback: The XFG "stratus" variant was first dedicated in January, according to the World Health Organization. The variant made little noise in the United States during the first half of the year. However, in June, the "stratus" variant accounted for 14% of cases, according to the CDC, which is the third-highest among all variants. XFG is a combination of the LF.7 and LP.8.1.2 variants, the latter of which is the second-most prominent strain in the U.S., per the CDC. Yes, but: Though the WHO has placed XFG on its watchlist, and it may be more adept at evading our immune defenses, the "stratus" variant was deemed as a "low" public health risk as recent as June. Are "Stratus" variant symptoms different? The "stratus" variant symptoms haven't been seen as any different than other recent COVID-19 variants. The common COVID-19 symptoms outlined by the CDC — fever, chills, cough, sore throat and congestion — still apply.
Yahoo
4 days ago
- Yahoo
Vaccines hold tantalizing promise in the fight against dementia
Over the past two centuries, vaccines have been critical for preventing infectious diseases. The World Health Organization estimates that vaccination prevents between 3 million and 5 million deaths annually from diseases like diphtheria, tetanus, influenza, measles and, more recently, COVID-19. While there has long been broad scientific consensus that vaccines prevent or mitigate the spread of infections, there is new research suggesting that the therapeutic impact might go beyond the benefit of preventing infectious diseases. An April 2025 study published in the prominent journal Nature found tantalizing evidence that the herpes zoster – or shingles – vaccine could lower the risk of dementia in the general population by as much as 20%. We are a team of physician scientists with expertise in the clinical and basic science of neurodegenerative disorders and dementia. We believe that this study potentially opens the door to other breakthroughs in understanding and treating dementia and other degenerative disorders of the brain. A role for vaccines in reducing dementia risk? One of the major challenges researchers face when trying to study the effects of vaccines is finding an unvaccinated 'control group' for comparison – a group that is similar to the vaccine group in all respects, save for the fact that they haven't received the active vaccine. That's because it's unethical to assign some patients to the control group and deprive them of vaccine protection against a disease such as shingles. The Nature study took advantage of a policy change in Wales that went into effect in 2013, stating that people born on or after September 2, 1933, were eligible for the herpes zoster vaccination for at least a year, while those born before that cutoff date were not. The vaccine was administered to prevent shingles, a painful condition caused by the same virus that causes chickenpox, which can lie dormant in the body and be reactivated later in life. The researchers used the policy change as a natural laboratory of sorts to study the effect of shingles vaccination on long-term health outcomes. In a statistically sophisticated analysis of health records, the team found that the vaccine reduced the probability of getting dementia by one-fifth over a seven-year period. This means that people who received the shingles vaccine were less likely to develop clinical dementia over the seven-year follow-up period, and women benefited more than men. The study design allowed researchers to compare two groups without actively depriving any one group of access to vaccination. The two groups were also of comparable age and had similar medical comorbidities – meaning similar rates of other medical conditions such as diabetes or high blood pressure. Results from this and other related studies raise the possibility that vaccines may have a broader role in experimental therapeutics outside the realm of infectious diseases. These studies also raise provocative questions about how vaccines work and how our immune system can potentially prevent dementia. How vaccines might be protective One scientific explanation for the reduction of dementia by the herpes zoster vaccine could be the direct protection against the shingles virus, which may play a role in exacerbating dementia. However, there is also the possibility that the vaccine may have conferred protection by activating the immune system and providing 'trained immunity,' in which the immune system is strengthened by repeated exposure to vaccines or viruses. The study did not differentiate between different types of dementia, such as dementia due to Alzheimer's disease or dementia due to stroke. Additionally, researchers cannot draw any definitive conclusions about possible mechanisms for how the vaccines could be protective from an analysis of health records alone. The next step would be a prospective, randomized, double-blind, placebo-controlled study – the 'gold standard' for clinical trials in medicine – to directly examine how the herpes zoster vaccine compares with a placebo in their ability to reduce the risk of dementia over time. Such studies are necessary before any vaccines, as well as other potential therapies, can be recommended for routine clinical use in the prevention of dementia. The challenges of untangling dementia Dementia is a major noncommunicable disease that is a leading cause of death around the world. A January 2025 study provided updated figures on lifetime dementia risk across different subsets of the U.S. population. The researchers estimate that the lifetime risk of dementia after age 55 is 42% – more than double earlier estimates. The dementia risk was 4% by age 75, and 20% by age 85, with the majority of risk occurring after 85. The researchers projected that the number of new cases of dementia in the U.S. would double over the next four decades from approximately 514,000 cases in 2020 to 1 million in 2060. Once considered a disease largely confined to the developed world, the deleterious effects of dementia are now apparent throughout the globe, as life expectancy increases in many formerly developing countries. While there are different forms of dementia with varying clinical manifestations and underlying neurobiology, Alzheimer's disease is the most common. Prospective studies that specifically test how giving a vaccine changes the risk for future dementia may benefit from studying patient populations with specific types of dementia because each version of dementia might require distinct treatments. Unfortunately, for the past two to three decades, the amyloid hypothesis of Alzheimer's disease – which posits that accumulation of a protein called amyloid in the brain contributes to the disorder – dominated the scientific conversation. As a result, most of the efforts in the experimental therapeutics of Alzheimer's disease have focused on drugs that lower the levels of amyloid in the brain. However, results to date have been modest and disappointing. The two recently approved amyloid-lowering therapies have only a minimal impact on slowing the decline, are expensive and have potentially serious side effects. And no drug currently approved by the Food and Drug Administration for clinical use reverses the cognitive decline. Studies based on health records suggest that past exposure to viruses increase the risk of dementia, while routine vaccines, including those against tetanus, diphtheria, pertussis, pneumonia, shingles and others, reduce the risk. Innovation and an open mind There is sometimes a tendency among scientists to cling to older, familiar models of disease and a reluctance to move in more unconventional directions. Yet the process of doing science has a way of teaching researchers like us humility, opening our minds to new information, learning from our mistakes and going where that data takes us in our quest for effective, lifesaving therapies. Vaccines may be one of those paths less traveled. It is an exciting possibility that may open the door to other breakthroughs in understanding and treating degenerative disorders of the brain. This article is republished from The Conversation, a nonprofit, independent news organization bringing you facts and trustworthy analysis to help you make sense of our complex world. It was written by: Anand Kumar, University of Illinois Chicago and Jalees Rehman, University of Illinois Chicago Read more: Whooping cough is making a comeback, but the vaccine provides powerful protection Until a coronavirus vaccine is ready, pneumonia vaccines may reduce deaths from COVID-19 Monkeypox vaccines: A virologist answers 6 questions about how they work, who can get them and how well they prevent infection Jalees Rehman receives funding from NIH. Anand Kumar does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment. Solve the daily Crossword
